In summary, four promising biomarkers (LGMN, DLL1, ERBB3, and DPPIV) that have the potential to serve as diagnostic biomarkers or therapeutic targets for AAA were discovered in this study. The gene discussed is LGMN; the disease is triple-A syndrome.